Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to -$2.4 million.

  • Journey Medical's Cash from Operations fell 10596.37% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.9 million, marking a year-over-year increase of 8589.27%. This contributed to the annual value of -$9.1 million for FY2024, which is 27417.94% down from last year.
  • Latest data reveals that Journey Medical reported Cash from Operations of -$2.4 million as of Q3 2025, which was down 10596.37% from -$942000.0 recorded in Q2 2025.
  • In the past 5 years, Journey Medical's Cash from Operations registered a high of $18.7 million during Q3 2023, and its lowest value of -$16.5 million during Q4 2023.
  • In the last 5 years, Journey Medical's Cash from Operations had a median value of -$2.4 million in 2025 and averaged -$1.4 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 35744.3% in 2023, then plummeted by 42500.0% in 2024.
  • Over the past 5 years, Journey Medical's Cash from Operations (Quarter) stood at -$3.2 million in 2021, then decreased by 19.65% to -$3.8 million in 2022, then plummeted by 330.66% to -$16.5 million in 2023, then soared by 113.47% to $2.2 million in 2024, then tumbled by 207.1% to -$2.4 million in 2025.
  • Its Cash from Operations stands at -$2.4 million for Q3 2025, versus -$942000.0 for Q2 2025 and -$2.8 million for Q1 2025.